Single-cell sequencing analyses of CRC samples from patients undergoing PD-1 blockade therapy at multiple time points have revealed insights into the evolution of local and systemic immunity, as well as the coordinated cellular responses associated with therapy, helping to pinpoint optimal drug administration timing and developing new strategies to improve immunotherapy responses in CRC patients [137]. Here, PDCD1 is linked to colorectal carcinoma.